Beta-lactams kill by time-dependent bactericidal activity: efficacy correlates with the fraction of the dosing interval that free drug exceeds the minimum inhibitory concentration (fT > MIC). Extending the infusion duration (typically 3–4 hours) maximizes fT > MIC without increasing the total daily dose. The BLING III trial (JAMA 2024, n = 7,031 critically ill patients with sepsis) demonstrated that continuous or extended infusion of piperacillin-tazobactam or meropenem reduced 90-day all-cause mortality versus intermittent bolus dosing (24.9% vs 26.8%; adjusted difference −1.9%; 95% CI −3.9 to 0.1; p = 0.047 unadjusted).
| Drug | EI Dose (normal renal) | Infusion Duration | Intermittent Equivalent |
|---|---|---|---|
| Piperacillin-tazobactam | 3.375 g q8h (serious/nosocomial: 4.5 g q8h) | 4 hours | 3.375 g q6h over 30 min |
| Meropenem | 1 g q8h (severe/resistant: 2 g q8h) | 3 hours | 1 g q8h over 30 min |
| Cefepime | 2 g q8h | 3–4 hours | 2 g q8h over 30 min |
Some institutions use continuous infusion (CI) over 24 h rather than 3–4 h EI. CI achieves steady-state fT > MIC but requires dedicated IV access and attention to stability limits.
| Drug | Diluent | Room Temp Stability | Refrigerated (4 °C) | Clinical Note |
|---|---|---|---|---|
| Piperacillin-tazobactam | NS | 24 h | 48 h | Preferred diluent for EI |
| Piperacillin-tazobactam | D5W | 12 h | 24 h | Adequate for 4 h EI; verify per product |
| Meropenem | NS | 6 h | 24 h | Mix fresh; 3 h EI safe, 4 h EI marginal |
| Meropenem | D5W | 4 h | 12 h | Avoid for EI; use NS |
| Cefepime | NS or D5W | 24 h | 7 d | Most stability-friendly for EI |
Meropenem is the stability bottleneck. Always dilute in NS (not D5W) for EI. Verify against your institution's IV stability references; product-specific data may vary by manufacturer and concentration.
| Drug | CrCl >40 | CrCl 20–40 | CrCl <20 | HD (give post-HD or supplement) |
|---|---|---|---|---|
| Piperacillin-tazobactam | Standard EI | 3.375 g q8h EI or 2.25 g q6h | 2.25 g q8h | 2.25 g q8h (supplement 0.75 g post-HD) |
| Meropenem | Standard EI | 1 g q12h (or EI q12h) | 500 mg q12h | 500 mg–1 g q24h (give after HD) |
| Cefepime | Standard EI | 2 g q12h | 1 g q24h | 1 g q24h (supplement 1 g after HD) |
EI renal dosing is institution-specific and not universally standardized. The intervals above reflect common practice derived from FDA labeling for intermittent dosing, adapted to EI by pharmacokinetic modeling. Always verify against local protocol.